

October 14, 2025

BF/COR/2025/10-01

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.

Dear Sir,

MATERIAL INFORMATION

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

We are pleased to inform you that BF Biosciences Limited ("the Company") has successfully launched its product Zeptide® (Tirzepatide) in an easy-to-use pre-filled syringe. Tirzepatide is a synthetic polypeptide molecule that acts as a dual agonist for the GLP-1 and GIP receptors, meaning it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor pathways. Tirzepatide is approved by US Food and Drug Administration (FDA) for treating type 2 diabetes mellitus (T2DM) and obesity.

Zeptide® is manufactured at the Company's new state-of-the-art European prefilled syringes facility. The pre-filled syringe is in a patient-friendly format that eliminates dosing errors. Zeptide® has been tested for quality, chemical structure and potency at the leading biological mass spectrometry facility in the US and at a leading national university in Pakistan. The development of Zeptide® was part of the IPO proceeds utilization in the prospectus.

Pakistan has the world's highest prevalence of diabetes. Even more alarmingly, 9 million individuals living with diabetes remain undiagnosed, and half of those who do know, struggle to manage it effectively. According to the WHO, 57% of women and 41% of men in Pakistan are overweight or obese. Obesity increase the risk of Type 2 diabetes by 7 times.

As the 1st Biopharmaceutical Plant in Pakistan, BF Biosciences Limited has remained committed to the production of essential medicines for the treatment of HCV, Cancer, Cardiology, Diabetes, nephrology and other therapeutic areas for over a decade. We are confident that the launch of Zeptide® will have a positive impact on the Company's growth and will further strengthen our mission to address critical unmet patient needs.

Head Office/Biotech Factory:
5-K.M- Sunder Raiwind Road
Raiwind Lahore, Pakistan.
Office phones: +92-42-36026700
Fax: +92-42-36026701-2
Factory phones: +92-308-5053135
Fax: +92-42-36026791

Registered Office:
197-A,
The Mall Rawalpindi, 46000
Pakistan.
Phones: +92-51-4252155-57
Fax: +92-51-4252153

Sales Office: Lahore
43-Al Noor Building,
Bank Square, The Mall,
Lahore, Pakistan.
Phones: +92-42-37358194
Fax: +92-42-37313680

Sales Office: Karachi
House No.9, Maqbool Corporate
Society Shahrah-e-Faisal Karachi,
Pakistan.
Phones: +92-21-34386852
Fax: +92-21-34386754



BF BIOSCIENCES LIMITED
A Subsidiary of FEROSONS LABORATORIES LIMITED

BIOSCIENCES

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Thank you.

Yours truly,

Abdur Rehman
Company Secretary

CC: Director Enforcement – Securities and Exchange Commission of Pakistan.

Head Office/Biotech Factory:
5-K.M- Sunder Raiwind Road
Raiwind Lahore, Pakistan.
Office phones: +92-42-36026700
Fax: +92-42-36026701-2
Factory phones: +92-308-5053135
Fax: +92-42-36026791

Registered Office:
197-A,
The Mall Rawalpindi, 46000
Pakistan.
Phones: +92-51-4252155-57
Fax: +92-51-4252153

Sales Office: Lahore
43-Al Noor Building,
Bank Square, The Mall,
Lahore, Pakistan.
Phones: +92-42-37358194
Fax: +92-42-37313680

Sales Office: Karachi
House No.9, Maqbool Corporative
Society Shahrah-e-Faisal Karachi,
Pakistan.
Phones: +92-21-34386852
Fax: +92-21-34386754

email: info@bfbio.com